Navigation Links
Orexigen® Therapeutics Reports Third Quarter Financial Results
Date:11/8/2011

>Anticipated reduction in predicted 10-year cardiovascular risk among Contrave treated patients from the Phase 3 COR program using a variety of validated risk models.
  • An imaging study showing that Contrave activated regions of the brain involved in controlling the response to food cues.
  • New analyses from the COR-I and COR-BMOD Phase 3 studies highlighting weight loss among subjects completing one year of therapy.  

  • The Company continues to expect cash expenditures for the second half of 2011 to be substantially lower than for the first half of 2011. The Company does anticipate a substantial increase in planned expenditures in 2012 as the major activities for the CVOT get underway once the details of the protocol are finalized and a clinical research organization to execute the trial is engaged.  The Company plans to provide a more detailed update on the specifics of the trial as well as additional financial guidance in the first quarter of 2012.

    About ContraveContrave, an investigational combination therapy of naltrexone HCl and bupropion HCl, was studied for its ability to help people with obesity initiate and sustain weight loss of at least 5 percent of their starting body weight in one year. Contrave was submitted for U.S. regulatory approval in March 2010. The original submission was based on multiple clinical trials that evaluated Contrave in more than 4500 patients. Orexigen received a Complete Response letter from the FDA on January 31, 2011.

    About Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave has completed Phase 3 clinical trials, and the Company's other product candidate, Empatic(TM), has completed Phase 2 clinical trials. Each of the components of the Company's product candidates has already received regulatory approval and has been commercialized previously. Further information about the Company can be found at '/>"/>

    SOURCE Orexigen Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
    2. Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September 30, 2010
    3. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
    4. Orexigen® Therapeutics Announces Corporate Realignment
    5. Orexigen® Therapeutics Announces Upcoming Data Presentation at the American College of Cardiology Annual Scientific Meeting
    6. Orexigen® Therapeutics Presents Additional Contrave® Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring
    7. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
    8. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
    9. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
    10. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
    11. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/14/2014)... MD (PRWEB) January 14, 2014 ... to developing innovative information technology solutions for patients, ... health care stakeholders, announced today the signing of ... US Food and Drug Administration (FDA). This ...
    (Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
    (Date:1/14/2014)... 14, 2014 During the 1600’s through the ... “The Doctor’s Plague.” In this time period, doctors did not ... at times, to the death of vulnerable patients. In the ... that they may be unwittingly transmitting herpes viruses to their ...
    (Date:1/14/2014)... 14, 2014 BioMedomics, Inc. , a ... diagnostic platforms and novel disease specific POC tests, announced today ... netting a total of $690,000. The investment is from private ... company. This group of private investors has significant successful experience ...
    Breaking Biology Technology:Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2
    ... just the expected crowd of educators is congregating at ... Conference that runs through Friday; as the technologies ... fields involved. In addition to K-12 and higher education ... and military organizations. , ,Distance Learning 2005 is addressing ...
    ... The Centers for Medicare and Medicaid Services plan to officially ... Vista within the next few weeks, according to news accounts ... ,CMS officials hope that providing the new program, known as ... records by private clinicians. , ,Vista, a software program used ...
    ... Ann Stunden, director of the Division of Information Technology ... 2005 award for information technology leadership from the national ... for "strong and ground-breaking leadership in the information technology ... ago." , ,A co-founder and executive director of ...
    Cached Biology Technology:Education conference focusing on importance of integrating technology 2Education conference focusing on importance of integrating technology 3Education conference focusing on importance of integrating technology 4
    (Date:7/9/2014)... selection for traits that are attractive to the opposite ... to mate, the tail of male peacocks being an ... Riverside have now found that sexual selection and "placentation" ... Describing the life histories of more than 150 species ... that species with placentas tend to have males that ...
    (Date:7/9/2014)... nature,s ability to split the water molecule during ... artificial photosynthesis for clean, green and renewable energy ... scientists led by researchers with the Lawrence Berkeley ... Accelerator Laboratory. , Working at SLAC,s Linac ... x-ray laser, the researchers were able to take ...
    (Date:7/9/2014)... traumatic injuries have identified an immune marker that ... hospital-acquired infection. The study, led by clinician-scientists at ... in the journal Shock , is part ... the clinical implementation of quick-turnaround immune function tests ... damage following critical illness or injury in pediatric ...
    Breaking Biology News(10 mins):Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4Postcards from the photosynthetic edge 2Postcards from the photosynthetic edge 3Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
    ... took place in Florence last week. It provided us with some ... Did life begin on Mars rather than on earth?, ... "Terror Bird", was probably a herbivore Goldschmidt2014 is ... June, 2014, so if you want to attend, put the dates ...
    ... estimate that there is a minimum of 320,000 viruses in ... a majority of them, they say, could provide information critical ... This undertaking would cost approximately $6.3 billion, or $1.4 billion ... fraction of the economic impact of a major pandemic like ...
    ... Candida albicans is a common fungus found living in, ... species causes no harm to humans unless it can breach ... or death. It is known as an opportunistic pathogen that ... New research, presented today at the Society for General Microbiology,s ...
    Cached Biology News:First estimate of total viruses in mammals 2First estimate of total viruses in mammals 3First estimate of total viruses in mammals 4Research identifies how mouth cells resist Candida infection 2
    ... Cycler unit is an inexpensive personal or mini ... PCR process. Lightweight, with a small footprint, it ... including the researcher's desk. , The Gene Cycler ... do not have access to a large laboratory ...
    ... Select Immunophosphatase Secondary Detection System is intended ... Prediluted Primary Antibody reagents, which contain rat ... of antigens by light microscopy in paraffin-embedded ... System may also be used with other ...
    ... RNA stain is used to stain and ... agarose gels and does not interfere with ... nm transilluminator, the stain emits a red-orange ... film or with a CCD camera-based gel ...
    ... efficient interfacing with mass spectrometry. Improved ... demands for benefits like these have ... routine applications. Standard HPLC systems, however, ... to operate with smaller bore columns ...
    Biology Products: